&w=3840&q=100)
Lupin share price increases on rolling out eye medication; details here
Around 10:20 AM, Lupin share price continued to trade higher, up 1.07 per cent at ₹1,950.40 per share. In comparison, BSE Sensex was trading 0.22 per cent lower at 82,456.51 levels.
Why did Lupin share price rise today?
Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market.
In a press release, the company said, 'Global pharma major Lupin Limited (Lupin) today announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent is bioequivalent to Lotemax Ophthalmic Suspension, 0.5 per cent, of Bausch & Lomb Inc.'
The drug is a generic version of Bausch & Lomb's Lotemax, and is used to treat steroid-responsive inflammatory conditions of the eye, including conjunctivitis, keratitis, iritis, and post-operative inflammation.
According to IQVIA MAT data for May 2025, the reference listed drug (RLD) Lotemax had estimated annual sales of around USD 55 million in the US. Track Stock Market LIVE Updates
Lupin Q4 results
The pharma major Lupin reported a 112.4 per cent year-on-year (Y-o-Y) jump in consolidated net profit at ₹782.4 crore for Q4FY25, compared to ₹368.2 crore in the year-ago period.
Revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, up from ₹4,961 crore in Q4FY24. However, on a sequential basis, profit declined 8.9 per cent and revenue slipped 1.7 per cent.
Operationally, Ebitda grew 34.3 per cent Y-o-Y to ₹1,371 crore, while the Ebitda margin improved to 24.8 per cent from 21 per cent in the same quarter last year.
About Lupin
Lupin is among the leading Indian multinational pharmaceutical companies headquartered in Mumbai, known for its expertise in developing and commercialising generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs).
With operations spanning over 100 countries, including key markets like the US, India, South Africa, and regions across Asia Pacific, Latin America, Europe, and the Middle East, Lupin has established itself as a global player.
The company holds strong positions in therapeutic areas such as cardiovascular, diabetology, asthma, paediatrics, and central nervous system (CNS) disorders. Notably, it is also a global leader in anti-tuberculosis and cephalosporin segments.
Founded in 1968 by Desh Bandhu Gupta with a mission to combat life-threatening infectious diseases, Lupin has grown into a pharmaceutical powerhouse with a robust global footprint.
It operates multiple manufacturing facilities in India, including sites at Mandideep, Ankleshwar, Tarapur, and Vadodara, supported by a network of research centers and a large workforce. In addition to its pharmaceutical business, the company has expanded into diagnostics through its wholly owned subsidiary, Lupin Diagnostics, which operates a national reference laboratory in Navi Mumbai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
24 minutes ago
- Time of India
BGO and Aditya Birla Sun Life AMC invest ₹350 crore in Namo Realtech to fuel real estate expansion
Real estate credit platform of BGO, a global real estate investment management advisor and Aditya Birla Sun Life AMC has invested Rs 350 crore in debt to NCR-based Namo Realtech to fund its expansion in the real estate sector. Namo Realtech is currently executing 2 projects in collaboration with Max Estates , spread over 30 acres with approximately 6.4 million square feet under development. The company holds an additional land bank, and is in the process of acquiring further land assets on which it intends to collaborate with established developers. Explore courses from Top Institutes in Please select course: Select a Course Category Design Thinking Others MBA Data Analytics Public Policy CXO others Management Artificial Intelligence Degree PGDM Data Science MCA Project Management Cybersecurity healthcare Technology Healthcare Finance Data Science Operations Management Product Management Digital Marketing Leadership Skills you'll gain: Duration: 22 Weeks IIM Indore CERT-IIMI DTAI Async India Starts on undefined Get Details 'India's residential market continues to show strong potential, and this transaction reflects our confidence in its sustained growth,' said Bharat Khanna, Head of India at BGO. The platform has committed to 9 projects across 5 cities focusing on post approval projects with established real estate partners. 'India's real estate sector has seen an increasing transformation in recent years with the help of government initiatives like GST and RERA. The funding is a testament to our shared vision of supporting high-value projects and driving long-term value creation,' said A Balasubramanian, Managing Director & CEO, Aditya Birla Sun Life AMC Ltd. With the Namo Realtech deal, the platform has committed USD $100 Million across 10 deals with 7.8 million sqft of area under management. The platform targets to achieve USD 1 Billion of deployed capital under this strategy by 2028. AZB & Partners, Quantum and Trilegal acted as advisors on the transaction. Namo Realtech plans to launch its next project, a premium residential project in Gurgaon in collaboration with Max Estates. 'As we continue to scale, this investment will allow us to accelerate our future plans with regard to new projects that are already in the pipeline and at fairly advanced stages of discussion with other potential collaborators,' said Mohit Jain, Managing Director at Namo Realtech. Mohit Jain, was responsible for establishing Krisumi Corporation in India in a Joint Venture with Sumitomo Corporation of Japan. Aditya Birla Capital Limited and Sun Life (India) AMC Investments Inc. are the promoters and major shareholders of Aditya Birla Sun Life AMC Limited (ABSLAMC), which is primarily the investment manager of Aditya Birla Sun Life Mutual Fund.
Time of India
27 minutes ago
- Time of India
Stock market update: Nifty IT index falls 0.38% in a weak market
NEW DELHI: The Nifty IT index traded negative around 11:02AM(IST)on Monday in a weak market. MphasiS Ltd.(up 3.38 per cent), Coforge Ltd.(up 1.77 per cent), Oracle Financial Services Software Ltd.(up 1.19 per cent) and LTIMindtree Ltd.(up 0.55 per cent) were among the top gainers. Explore courses from Top Institutes in Please select course: Select a Course Category Data Analytics Cybersecurity Operations Management Degree Others Data Science Artificial Intelligence Healthcare Finance Data Science MBA Management Product Management Digital Marketing Leadership Technology CXO others Design Thinking PGDM healthcare MCA Project Management Public Policy Skills you'll gain: Data Analysis & Visualization Predictive Analytics & Machine Learning Business Intelligence & Data-Driven Decision Making Analytics Strategy & Implementation Duration: 12 Weeks Indian School of Business Applied Business Analytics Starts on Jun 13, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Thanh Phuoc: Unsold Furniture Liquidation 2024 (Prices May Surprise You) Unsold Furniture | Search Ads Learn More Wipro Ltd.(down 2.82 per cent), Tata Consultancy Services Ltd.(down 0.88 per cent), Infosys Ltd.(down 0.59 per cent), HCL Technologies Ltd.(down 0.58 per cent) and Tech Mahindra Ltd.(down 0.12 per cent) were the top losers on the index. The Nifty IT index was down 0.38 per cent at 35489.3 at the time of writing this report. Benchmark NSE Nifty50 index was down 0.05 points at 24836.95, while the BSE Sensex was down 38.59 points at 81424.5. Live Events Among the 50 stocks in the Nifty index, 28 were trading in the green, while 22 were in the red. Shares of Vodafone Idea , Ola Electric Mobilit, PC Jeweller , Indian Energy Exchg and JP Power were among the most traded shares on the NSE. Shares of Times Guaranty , Vimta Labs , Manorama Ind, Sudarshan Chemical and Shree Pushkar Chem hit their fresh 52-week highs in today's trade, while Supreme Engineering , Reliance Comm, Marshall Machines , SKIL Infrastructure and JITF Infralogistics hit fresh 52-week lows in trade.
&w=3840&q=100)
Business Standard
40 minutes ago
- Business Standard
Laurus rallies 6%, hits new high on strong Q1; brokerages see more upside
Laurus Labs share price today Shares of Laurus Labs hit a new high of ₹889.3, surging 6 per cent on the BSE in Monday's intra-day trade in an otherwise subdued market after the company reported strong earnings for the June 2025 quarter (Q1FY26). The BSE Sensex was up 0.06 per cent at 81,512 at 10:20 AM. In the past one month, the stock of pharmaceutical company has outperformed the market by soaring 27 per cent, as compared to 2.7 per cent decline in the BSE Sensex. It has zoomed 128 per cent from its 52-week low of ₹390.30 on August 8, 2024. Laurus Labs - Q1FY26 performance, outlook Laurus delivered a solid performance in Q1, in line with market expectations. The management said they are pleased to see sustained growth momentum fueled by increasing uptake in the contract development and manufacturing organisation (CDMO) deliveries and healthy business fundamentals. The company has achieved revenues of ₹1,570 crore, representing 31 per cent year-on-year (YoY) growth and earnings before interest, taxes, depreciation, and amortization (EBITDA) of ₹389 crore, representing 127 per cent growth. The EBITDA margins improved substantially to 24.8 per cent, from 14.3 per cent in Q1FY25, supported by continuing operating leverage. Gross margins stood strong at 59.4 per cent due to favorable CDMO mix and ongoing process improvement initiatives. Profit after tax stood ₹161.1 crore, driven by a favorable product mix and strong operational performance. Laurus has made a healthy progress to start the year with increasing contributions from the CDMO business and continued advancement of pipeline projects, supported by Generic Formulation (FDF). The management said the company is moving ahead with strong focus on commercial execution realizing the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities. ALSO READ | Brokerages firm see more upside in stock price of Laurus The CDMO growth was driven by several mid-to-late stage NCE deliveries and steady increase in sales from new manufacturing assets. Out of ₹3,200 core of capex that the company has incurred during FY22-25, almost ~75 per cent was earmarked towards active pharmaceutical ingredient (API) / CDMO. The company is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years. The CDMO contribution has also gone up from ~16 per cent to 33 per cent which has led to a significant margin expansion. ICICI Securities said they continue to monitor progress on these driving factors which in a way are expected to change the business mix in favour of these segments in lieu of anti-retroviral (ARV). Analysts at Choice Equity Broking believe Laurus is evolving from a traditional Generics player to a CDMO (Synthesis)–led model, with the segment targeted to reach ~50 per cent of revenues in the long term. Given the higher-margin profile of CDMO and operating leverage as new manufacturing assets ramp and current underutilization narrows, the brokerage firm expects sustained margin expansion. Analysts maintain 'buy' rating on the stock with revised target price of ₹1,025 against previous target price of ₹750. Motilal Oswal Financial Services raise earnings estimates by 16 per cent/7 per cent for FY26/FY27, factoring in strong tailwinds in CDMO segment led by 110+ active pipeline projects/ramp-up from new manufacturing facilities, additional contracts in generic FDF segment, and margin expansion from scale. Considering a 63 per cent earnings compounded annual growth rate (CAGR) over FY25-27, the brokerage firm value Laurus at 56x 12M forward earnings to arrive at a target price of ₹970. Reiterate BUY.
